



## **Chlorion Pharma Appoints Dr. John Andrews and Dr. Terrence Doyle to its Scientific Advisory Board**

LAVAL, QC, March 11 -- Chlorion Pharma Inc. today announced that Dr. John Andrews and Dr. Terry Phillips will serve on the company's Scientific Advisory Board.

Dr. Jeffrey Coull, Chlorion's President & CEO, summed up the company's enthusiasm with the recent appointments by saying: "John and Terry are two of the top experts in drug development in the world. Taken together with the existing members of the Scientific Advisory Board, I believe that Chlorion now possesses one of the top CNS-focused SABs around".

Dr. Andrews is currently the President and COO of NeurAxon Inc., a leader in the discovery and development of pain therapeutics focused on the inhibition of neuronal nitric oxide synthase. Prior to this, Dr. Andrews was Vice President of CNS Drug Discovery at Janssen Pharmaceuticals (a Johnson & Johnson company).

Dr. Doyle is a highly experienced medicinal chemist, who most recently served as the Vice President of Research and Development at Vion Pharmaceuticals. Before working with Vion, Dr. Doyle was Executive Director of Chemistry at Bristol-Myers Squibb.

Drs. Andrews and Doyle join Dr. Yves De Koninck and Dr. Franz Hefti on Chlorion's Scientific Advisory Board.

### About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at [www.chlorion.com](http://www.chlorion.com).

##